Ainos Inc. (AIMD)
Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization
Alto Neuroscience Inc. (ANRO)
Alto Neuroscience, Inc. - Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression
Biofrontera Inc. (BFRI)
Biofrontera Notification (BFRI)
INmune Bio Inc. (INMB)
CRISPR Therapeutics (CRSP)
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
(UNDEFINED)
Tectonic Therapeutic Joins Russell 3000® Index
Assembly Biosciences Inc. (ASMB)
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
Eyenovia Inc. (EYEN)
Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement
Spectral AI (MDAI)
Spectral AI Announces Submission to FDA of itsDeepView® System
Tyra Biosciences Inc. (TYRA)
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
Tempest Therapeutics Inc. (TPST)
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Corbus Pharmaceuticals Holdings Inc. (CRBP)
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity